By Brian Marckx, CFA NASDAQ:ICAD Q3 2017 Results: Revenue Dead-On With Our Estimate. Solid Results From Both Detection and Therapy… iCAD ( ICAD ) reported Q3 financial results for their third quarter ending September 30th. As a reminder, we noted in our Q2 update in August that we would be very surprised if Q2 revenue, of $6.4M, did not represent a valley and regular sequential growth did not return in Q3. We were happy to see that Q3 results were largely in-line with our expectations. This includes revenue which came in dead-on with our number and, excluding a non-cash charge to goodwill, EPS was one penny better than what we modeled. Overall, we characterize Q3 as a solid quarter – from both a financial and operational perspective. On the financial side, ICAD saw solid revenue growth from both the detection and therapy segments, maintained relatively tight reins on expenses and turned in the lowest operating loss (ex-charges) in the last five quarters.